 | | |  Good morning. Markets don't just react to events, they overreact. That can lead to big profits for astute investors and traders. Right now, the market is focused heavily on inflation, and rightly so. But the fight to combat inflation is well under way. While last week's big headline news was the Federal Reserve raising interest rates 0.75%, a bigger trend is under way.
In the past year, mortgage rates have doubled, from just under 3% to 6% recently. That's a huge drag on potential activity in the housing market. And where that market goes, so goes the economy, given how much wealth the average American has in housing. While there's less leverage in the space compared to the housing crisis, lower home prices point to a massive drop in inflation over the next 6-12 months. As long as this deflation knocks out today's inflation, markets could be poised for a big rebound. But if the housing market overreacts to today's interest rate increases, which looks likely, then more pain ahead looks more likely.
Now here's the rest of the news: | | | | | | | | Invest In This Biotech Company Solving A $240B Problem | | | | | | Every year, over 600M patients suffering from osteoarthritis spend $240 billion on painkillers and other palliative solutions to the cartilage damage caused by this debilitating disease. These "band-aid" therapies are temporary and do not treat the root cause of osteoarthritis.
Enter Cytonics.
This private biotech startup has harnessed the therapeutic potential of a naturally occurring blood protein, called "A2M," to reverse cartilage deterioration in arthritic joints. Their first FDA approved A2M-based therapy has successfully treated over 8,000 patients, proving the therapeutic efficacy of A2M, and restoring patients' quality of life.
Backed by Johnson & Johnson and the NIH, Cytonics is developing a genetically engineered A2M variant that is more potent than the natural form. This lead drug candidate, "CYT-108," has been proven to restore up to 80% of cartilage damage caused by osteoarthritis in preclinical studies.
Cytonics' first-in-in-class CYT-108 will enter Phase 1 clinical trials later this year. Invest in Cytonics as they blaze toward their second FDA drug approval, and before this private biotech goes public. | |
| | |  | DOW 29,888.78 | -0.13% | | |  | S&P 3,674.84 | +0.22% | | | | | NASDAQ 10,798.35 | +1.43% | | | | | *As of market close | | | • | Stocks were closed Monday, in observation of Juneteenth. | | | | | | | |
| | | Keep Adding Big Tech Winners Amid This Bear Market | | | | Markets have rapidly repriced in the growth prospects for a number of companies. While some of the most speculative names have taken the biggest dive, even great companies that have remained profitable while showing slow and steady growth are at a point where they've oversold. For long-term investors, this marks the best point in years to buy growth at a respectable valuation. That's especially true when it involves companies playing to strong growth trends now.
» FULL STORY | | | | |
| | Insider Trading Report: Fastenal (FAST) | | | | Holden Lewis, CFO at Fastenal (FAST), recently added 1,000 shares. The buy increased his stake by nearly 12 percent, and came to a total price of just under $50,000. He was joined by another EVP, who also picked up 1,000 shares on the same day for about the same price. This adds to further insider buys in recent months, from company executives and directors alike. Going back over the past three years, there has been a mix of insider buys and sells.
» FULL STORY | | | | |
| | Unusual Options Activity: Carvana (CVNA) | | | | Shares of vehicle resale platform Carvana (CVNA) are down over 91 percent in the past year. One trader sees a rebound ahead for the stock in the next 18 months. That's based on the January 2024 $60 calls. With 577 days until expiration, 10,283 contracts traded compared to a prior open interest of 130, for a 95-fold surge in volume on the trade. The buyer of the calls paid $5.70 to get into the trade.
» FULL STORY | | | | |
| | • | Governments Float Gas Tax Break
A number of governments around the world are looking at ways to soften the high cost of gasoline right now. At the Federal level, the idea of a gas rebate card has been proposed. Many states and counties are looking to suspend their gasoline taxes, which can lead to an immediate price drop at the pump. | | | | • | Port Work Labor Talks Could Extend Supply Chain Issues
The International Longshore and Warehouse Union is in talks with management at 29 ports in the US. The current worker contract expires on July 1, and a strike or walkout could lead to over 16,000 workers preventing cargo ships from unloading. For now, both sides say they're willing to continue under current conditions until new terms are agreed to. | | | | • | Small Businesses Shedding Headcount
Companies with fewer than 50 employees have been losing total head count in the past few months. While it could be a sign of the economy slowing down, overall job growth has been strong. That makes rising wages and the challenges of offering strong benefits by smaller companies a potential explanation for the drop right now. | | | | • | Germany Looks to Expand Coal Use to Reduce Russian Gas Dependency
Germany is looking to fire up old coal-powered plants this winter, as the country looks to reduce its use of Russian natural gas. The goal is to prevent any supply shortage and brownouts during the winter season, even though coal can be one of the most carbon-heavy fossil fuels. | | | | • | Telegram Hits 700 Million Users
Communications app Telegram has hit over 700 million active monthly users. The platform is also looking to create a monthly premium tier, adding more features such as larger file sends and faster download speeds. The company expects the premium tier to allow them to move towards monetization of the app and its user base. | | |
| | | | TOP | | | NCLH | 10.116% | | | | CCL | 9.714% | | | | ENPH | 8.936% | | | | SEDG | 8.438% | | | | AAL | 6.415% | | | | BOTTOM | | | FANG | 8.52% | | | | COP | 8.475% | | | | DVN | 8.298% | | | | PXD | 8.17% | | | | CTRA | 7.3% | | | | |
| | |  | | Near-term recession has become a foregone conclusion for many investors; the only questions now are its duration and the severity of its impact on earnings. | | - Chris Harvey, Wells Fargo Securities head of equity strategy, on why investors have priced in a recession into financial markets, and why that may continue to impact the market through the next earnings season.  | |
| | Invest In This Biotech Company Solving A $240B Problem | | | | | | Every year, over 600M patients suffering from osteoarthritis spend $240 billion on painkillers and other palliative solutions to the cartilage damage caused by this debilitating disease. These "band-aid" therapies are temporary and do not treat the root cause of osteoarthritis.
Enter Cytonics.
This private biotech startup has harnessed the therapeutic potential of a naturally occurring blood protein, called "A2M," to reverse cartilage deterioration in arthritic joints. Their first FDA approved A2M-based therapy has successfully treated over 8,000 patients, proving the therapeutic efficacy of A2M, and restoring patients' quality of life.
Backed by Johnson & Johnson and the NIH, Cytonics is developing a genetically engineered A2M variant that is more potent than the natural form. This lead drug candidate, "CYT-108," has been proven to restore up to 80% of cartilage damage caused by osteoarthritis in preclinical studies.
Cytonics' first-in-in-class CYT-108 will enter Phase 1 clinical trials later this year. Invest in Cytonics as they blaze toward their second FDA drug approval, and before this private biotech goes public. | |
|
No comments:
Post a Comment